Journal
MOLECULAR NEURODEGENERATION
Volume 12, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/s13024-017-0165-0
Keywords
Alzheimer's disease; Amyloid precursor protein; Intraluminal vesicles; Multivesicular bodies; Tetraspanin-6
Categories
Funding
- Fonds Wetenschappelijk Onderzoek (FWO) Research Foundation [95508, G094414N]
- KU Leuven
- Flemish Government
- Opening the Future campaign of the Leuven Universiteit Fonds (LUF)
- Grants-in-Aid for Scientific Research [26290019] Funding Source: KAKEN
- Medical Research Council [G0601073, MR/N021738/1, MC_PC_17116] Funding Source: researchfish
- MRC [MC_PC_17116, MR/N021738/1, G0601073] Funding Source: UKRI
Ask authors/readers for more resources
Background: The mechanisms behind A beta-peptide accumulation in non- familial Alzheimer's disease (AD) remain elusive. Proteins of the tetraspanin family modulate A beta production by interacting to y secretase. Methods: We searched for tetraspanins with altered expression in AD brains. The function of the selected tetraspanin was studied in vitro and the physiological relevance of our findings was confirmed in vivo. Results: Tetraspanin-6 (TSPAN6) is increased in AD brains and overexpression in cells exerts paradoxical effects on Amyloid Precursor Protein (APP) metabolism, increasing APP-C-terminal fragments (APP-CTF) and A beta levels at the same time. TSPAN6 affects autophagosome- lysosomal fusion slowing down the degradation of APP-CTF. TSPAN6 recruits also the cytosolic, exosome-forming adaptor syntenin which increases secretion of exosomes that contain APP-CTF. Conclusions: TSPAN6 is a key player in the bifurcation between lysosomal- dependent degradation and exosome mediated secretion of APP-CTF. This corroborates the central role of the autophagosomal/lysosomal pathway in APP metabolism and shows that TSPAN6 is a crucial player in APP-CTF turnover.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available